| 摘要 |
Use of a compound of general formula (I) or salt thereof wherein R and R<4> are independently selected from hydrogen, halogen and C1-6 alkyl or haloalkyl, C2-6 alkenyl or haloalkenyl, C1-6 alkoxy, phenoxy, C1-6 alkylthio, phenylthio, primary and secondary amino or hydroxy groups and R<3> is hydrogen, hydroxy, a C1-6 alkyl or haloalkyl, C2-6 alkenyl or haloalkenyl or C1-6 alkoxy or haloalkoxy group is provided for the manufacture of a medicament for the treatment of neoplasms, particularly solid cancerous tumours characterised in that R<1> is selected from a C1-6 alkyl or haloalkyl group, -CO2R<5> where R<5> is hydrogen or a C1-6 alkyl or haloalkyl group, or a group -CH2-X where X is selected from groups of formula -S-R<6>, -O-R<6>, and (a) where R<6> is a hydrogen or a leaving group, the acid HR6 of which has a pKa of 10 or less and R<7> and R<8> are the same or different and are selected from C1-6 alkyl or haloalkyl or together with the interjacent nitrogen form a heterocyclic ring of 5 to 7 atoms optionally substituted by C1-4 alkyl or haloalkyl and R<2> is selected from hydrogen, C1-4 alkyl and haloalkyl or groups-(CH2)nCHR<9>R<10> of more than four carbon atoms where n is an integer of 0 to 2 and R<9> and R<10> are independently selected from a C1-4 alkyl or haloalkyl group, or R<9> and R<10> together with the interjacent carbon atom form a C3-7 cycloalkyl or cycloalkenyl ring optionally substituted with one or more C1-4 alkyl or haloalkyl, or C2-4 alkenyl or haloalkenyl groups. |
